TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11896424
Drug: Overall mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall mobilization chemotherapy regimens (DHAP or CPM)
Study: 9588637
Drug: Salbutamol via
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol via pressurised metered dose inhaler (PMDI)
Study: 20356487
Drug: Moxifloxacin-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin-based triple therapy (rabeprazole 10 mg twice a day, moxifloxacin 400 mg/day, amoxicillin 1000 mg twice a day)
Study: 20356487
Drug: Bismuth-based quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based quadruple therapy (rabeprazole 10 mg twice a day, bismuth salts 150 mg three times a day, clarithromycin 500 mg twice a day, metronidazole 400 mg twice a day)
Study: 18055472
Drug: Abatacept (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (approximately 10 mg/kg every 4 weeks)
Study: 18055472
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg every 8 weeks)
Study: 16035956
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg/d)
Study: 12514674
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C infusion with furosemide
Study: 12514674
Drug: Furosemide with
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide with vitamin C and kallikrein inhibitor (nafamostat mesilate)
Study: 10826586
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic spray
Study: 6541512
Drug: Conventional enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional enteric-coated tablet (ET)
Study: 6541512
Drug: Conventional aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional aspirin (control)
Study: 29948188
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (escitalopram)
Study: 25181575
Drug: 1000 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg of phylloquinone daily for 12 months (with Ca 500 mg/d and vitamin D3 10 μg/d)
Study: 25181575
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with Ca 500 mg/d and vitamin D3 10 μg/d)
Study: 23700589
Drug: Traditional text-/image-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional text-/image-based learning supplements
Study: 17963865
Drug: Diaphragm with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm with 6% CS gel
Study: 17963865
Drug: Diaphragm with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm with KY gel
Study: 17963865
Drug: CS gel
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS gel alone
Study: 11983451
Drug: Daily interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interferon alfa-2b (3 million units per day for 12 weeks then 3 million units three times per week for 24 weeks) and ribavirin (36 week treatment)
Study: 11983451
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b three times a week (alone or in combination with ribavirin)
Study: 9802051
Drug: Music intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music intervention during high-dose chemotherapy (48 hours of high-dose cyclophosphamide)
Study: 2545454
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg day‐1)
Study: 2545454
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg day‐1)
Study: 200435
Drug: Fosazepam 100
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosazepam 100 mg
Study: 31512716
Drug: Sevoflurane-based anaesthetic
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane-based anaesthetic regimen (1-3% sevoflurane inhalation during anaesthesia maintenance)
Study: 31512716
Drug: Propofol-based anaesthetic
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based anaesthetic regimen (6-10 mg/kg/h propofol infusion during anaesthesia maintenance)
Study: 24498845
Drug: Chelladaghi herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelladaghi herbal extract (suppository) administered every 12 hours from 24 hours before to 24 hours after surgery.
Study: 24498845
Drug: Chelladaghi herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelladaghi herbal extract (oral) administered from 24 hours before to 24 hours after surgery.
Study: 24498845
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered from 24 hours before to 24 hours after surgery.
Study: 20887365
Drug: Rufinamide (3,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufinamide (3,200 mg/day)
Study: 15329830
Drug: Doxylamine-pyridoxine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine-pyridoxine combination (5-12 tablets/day)
Study: 15329830
Drug: Doxylamine-pyridoxine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine-pyridoxine combination (1-4 tablets/day)
Study: 11432893
Drug: Topotecan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 0.5 mg/m²/d and carboplatin AUC of 4
Study: 11432893
Drug: Topotecan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 0.5 mg/m²/d and carboplatin AUC of 5
Study: 11432893
Drug: Topotecan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 0.75 mg/m²/d and carboplatin AUC of 5
Study: 11432893
Drug: Topotecan 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.0 mg/m²/d and carboplatin AUC of 5
Study: 11432893
Drug: Topotecan 1
Normalized name: topotecan 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1 mg/m²/d and carboplatin AUC of 5
Study: 8345497
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (atenolol, nifedipine, captopril)
Study: 27091810
Drug: mFOLFOX6 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 plus aflibercept (4 mg/kg)
Study: 22108774
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg once daily (first dose 400 mg) for 5 days
Study: 22108774
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg twice daily (first dose 200 mg) for 5 days
Study: 15516364
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (15 g down to 2.5 g daily)
Study: 11206017
Drug: Open-label dalteparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label dalteparin, administered before percutaneous coronary intervention within 7 days
Study: 8789431
Drug: Isotretinoin alone
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin alone (Roaccutan, Roche) 1 mg/kgr orally daily for 3 months or until remission achieved
Study: 8789431
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (Roferon‐A, Roche) 3 million units subcutaneously three times for 8 weeks plus isotretinoin 1 mg/Kg orally for 3 months or until remission achieved
Study: 26519549
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) vaccine
Study: 26519549
Drug: Standard subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard subcutaneous (SC) vaccine
Study: 12633915
Drug: Cocaine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 12.5 mg
Study: 12633915
Drug: Cocaine 25
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 25 mg
Study: 12633915
Drug: Cocaine 50
Normalized name: cocaine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 50 mg
Study: 11113721
Drug: Crataegus Special
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crataegus Special Extract WS 1442 (450 mg, standardized to 84.3 mg of oligomeric procyanidines)
Study: 9361129
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of Polypodium leucotomos (PL)
Study: 9361129
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Polypodium leucotomos (PL)
Study: 9361129
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (untreated or treated with oral psoralens)
Study: 26407909
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg kg‐1 per day topical CHE
Study: 26407909
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg kg‐1 per day topical CHE
Study: 20103694
Drug: Milnacipran 300
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran 300 mg bid
Study: 20103694
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg single dose)
Study: 10430348
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 2.0 atm with inhalation of 100% oxygen for 60 min, at 3 hours and 24 hours after hepatectomy
Study: 7539237
Drug: Liver resection
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver resection combined with pre‐ and post‐operative locoregional chemotherapy‐immunotherapy (Group B)
Study: 31330044
Drug: Soil heterogeneity
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soil heterogeneity (three soil types assigned to patches)
Study: 29738389
Drug: Endolymphatic sac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endolymphatic sac decompression with steroid injection (n=18)
Study: 29738389
Drug: Endolymphatic sac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endolymphatic sac decompression without steroid injection (n=17)
Study: 17592006
Drug: Variability in
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variability in formulations used to compound caffeine
Study: 15341667
Drug: Glutamine-enriched enteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched enteral nutrition (0.3 g/kg/day)
Study: 12297845
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (3 million units 3 times a week) plus ribavirin (1,000 mg/day) for 48 weeks
Study: 9503102
Drug: Carvedilol combined
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol combined with a diuretic
Study: 8301791
Drug: 22‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22‐mg nicotine patch
Study: 3382069
Drug: Immediate whole‐bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate whole‐bowel irrigation with a polyethylene glycol solution
Study: 3382069
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g oral activated charcoal followed by whole‐bowel irrigation
Study: 3382069
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal alone
Study: 25948437
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract 2% cream
Study: 23101282
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propafenone and bisoprolol (group B, n = 82)
Study: 20495925
Drug: Liquid taste
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid taste solutions with different concentrations of each tastant (sweet 0.03, 0.1, 0.4, 2 g/mL sucrose solution; sour 0.01, 0.05, 0.1, 0.15 mL citric acid; salty 0.025, 0.075, 0.15, 0.36 mL sodium chloride solution; bitter 0.0002, 0.0005, 0.001, 0.01 mL quinine hydrochloride)
Study: 20495925
Drug: Liquid taste
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid taste solutions
Study: 18946064
Drug: Alemtuzumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (12 mg or 24 mg per day) for 36 months
Study: 8986493
Drug: Diazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.5 mg/kg loading dose followed by 1 mg/kg infusion over 24 h)
Study: 31717728
Drug: Four 30‐min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 30‐min daily outdoor unstructured play periods for 8 weeks
Study: 26338726
Drug: Metronidazole group
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole group (lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg, metronidazole 400 mg)
Study: 26338726
Drug: Clarithromycin group
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin group (lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg, clarithromycin 500 mg)
Study: 21722580
Drug: General activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: General activities of daily living
Study: 2172535
Drug: Perilesional injections
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perilesional injections of alpha-interferon (twice-weekly)
Study: 24168257
Drug: Narlaprevir monotherapy
Normalized name: Paritaprevir
DrugBank: Paritaprevir (DB09297)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Narlaprevir monotherapy for one week
Study: 24168257
Drug: Narlaprevir/pegylated interferon-alpha-2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narlaprevir/pegylated interferon-alpha-2b combination therapy for two weeks
Study: 24168257
Drug: Narlaprevir dosing
Normalized name: Paritaprevir
DrugBank: Paritaprevir (DB09297)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Narlaprevir dosing
Study: 24168257
Drug: Narlaprevir treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narlaprevir treatment
Study: 6210867
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up
Study: 15005645
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg Phase 2 twice daily with meals
Study: 8872666
Drug: NG-mononmethyl-L-arginine infusion
Normalized name: L-Ng-monomethyl Arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-mononmethyl-L-arginine infusion
Study: 2574084
Drug: Somatostatin (SMS)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMS) infusion (4 micrograms/min)
Study: 2574084
Drug: Somatostatin (SMS)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMS) infusion
Study: 1097203
Drug: Oral ephedrine
Normalized name: ephedrine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ephedrine (25 mg)
Study: 30245189
Drug: Ruxolitinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (20 mg twice daily)
Study: 31730370
Drug: Augmented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented treatment (titrated risperidone)
Study: 31730370
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (placebo)
Study: 28805135
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (initially continuous dosing)
Study: 28805135
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing schedule (five‐week‐on and three‐week‐off)
Study: 28805135
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing schedule
Study: 23443947
Drug: Control (4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4% lidocaine cream and Tc-99m)
Study: 16972829
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 oral midazolam (M)
Study: 9247476
Drug: 9 MU
Normalized name: CHEMSTRIP 9 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 MU IFN in patients with intermediate virus load (10(4)‐10(5) copies/mL)
Study: 9247476
Drug: 6 MU
Normalized name: Pancrelipase 16 mu
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 MU IFN in patients with intermediate virus load (10(4)‐10(5) copies/mL)
Study: 3651531
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose infusion
Study: 3651531
Drug: Lactate and
Normalized name: Ammonium lactate and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate and Isoproterenol infusions
Study: 31038440
Drug: Weekly ballet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly ballet classes
Study: 26468478
Drug: Sour tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sour tea pill (500 mg)
Study: 21242557
Drug: EHR-based clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR-based clinical decision support for patients on low-dose aspirin
Study: 21242557
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care for patients on low-dose aspirin
Study: 16922930
Drug: Intranasal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal immunization with E-GTF (n = 7)
Study: 12893996
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of relaxation and imagery delivered on two evenings
Study: 9375877
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose amitriptyline (up to 30 mg nightly)
Study: 8269183
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (12 g/d for 3 weeks)
Study: 8269183
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (12 g/d for 3 weeks)
Study: 2994988
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 20 mg twice‐daily) and Hydrochlorothiazide (50 to 100 mg/day)
Study: 2994988
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (Hydrochlorothiazide (50 to 100 mg/day), Timolol (10 to 30 mg twice‐daily), Hydralazine (50 to 150 mg twice‐daily)
Study: 27603903
Drug: Diazoxide (DZX)
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazoxide (DZX) 4 mg/kg/d for 6 months
Study: 20171357
Drug: IAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN block administered with a peripheral nerve stimulator
Study: 18598837
Drug: Ciprofloxacin and
Normalized name: ciprofloxacin and ornidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin and hydrocortisone (CHC) 3 drops twice daily for 7 days
Study: 18598837
Drug: NPH +
Normalized name: INSULIN,NPH,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH + AMX (neomycin/polymyxin b/hydrocortisone with systemic amoxicillin)
Study: 8530574
Drug: Nafarelin (NAF;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (NAF; 400 micrograms, intranasal spray, twice daily)
Study: 8530574
Drug: Norethindrone (NOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone (NOR 1/35; 0.035 mg, daily, for 3 of 4 weeks)
Study: 8530574
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nafarelin and Norethindrone
Study: 7037351
Drug: Optisulin ‐depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optisulin ‐depot CS (25% dissolved porcine Des‐Phe‐insulin/insulin and 75% crystalline porcine insulin)
Study: 7037351
Drug: Depot Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depot Insulin Hoechst CS
Study: 7037351
Drug: Insulin Leo
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Leo Mixtard
Study: 23049590
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS) treatment for 6 weeks
Study: 18182872
Drug: Hand acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand acupuncture therapy using New Seoam Press Pellets number 1 for 4 weeks
Study: 16089103
Drug: Chemo-radiotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-radiotherapy (cisplatin + etoposide + early concurrent thoracic radiotherapy)
Study: 16089103
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin + etoposide)
Study: 8606523
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg talinolol
Study: 8606523
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg talinolol
Study: 8606523
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg talinolol
Study: 2291875
Drug: Medifoxamine 100
Normalized name: Medifoxamine
DrugBank: Medifoxamine (DB13219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medifoxamine 100 mg by i.v. infusion over 15 min
Study: 2291875
Drug: Medifoxamine 500
Normalized name: Medifoxamine
DrugBank: Medifoxamine (DB13219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medifoxamine 500 mg by mouth fasting
Study: 2291875
Drug: Oral Medifoxamine
Normalized name: Medifoxamine
DrugBank: Medifoxamine (DB13219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Medifoxamine